Loss of FCGR2B gene expression, and reduced surface expression of CD32B have been observed in activated B-cells of NOD mice, and human systemic lupus erythematosus patients (24–27), while a lower frequency of CD32B+ B-cells, and lower mean fluorescent intensity of CD32B expression have been observed in B-cells of rheumatoid arthritis patients compared to controls (23). The gene discussed is FCGR2B; the disease is systemic lupus erythematosus.